Studies immune cells in lung cancer, sarcoidosis and COPD
Studies immune cells in people with lung cancer, sarcoidosis or COPD.
Plain-language title generated from the registry record
Registry title: Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
Key facts
- Where
- Brussels, BelgiumSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with lung cancer, precancerous lung lesions, sarcoidosis or COPD, plus control volunteers without lung disease. It also takes some children with chronic granulomatous disease and adults having orthopedic surgery.
- Age
- Up to 80 years. No minimum age is given; children weighing at least 10 kg (22 lb) with chronic granulomatous disease can join.
- Sex
- All sexes can join.
- Disease stage
- Lung cancer or precancerous lung lesions. Sarcoidosis or COPD before any treatment. Control group: no known lung disease.
- Earlier treatment
- People with sarcoidosis or COPD must not have had any treatment yet. Those with chronic inflammatory lung disease cannot currently be on immunosuppressive therapy.
- Biomarker or test result
- Children and adolescents need chronic granulomatous disease (CGD) confirmed by genetic testing.
Main reasons for not taking part
- Systemic corticosteroid therapy above 10 mg/day prednisone (or equivalent)
- Acute infection at the time of joining
- Chronic inflammatory lung disease currently treated with immunosuppressive therapy
- Refusal or inability to give informed consent (or assent)
Read by machine on 12 November 2026.
Where in Belgium
- Cliniques universitaires Saint-LucBrussels, BelgiumContact: Frank Aboubakar Nana, MD; PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Université Catholique de Louvain
- Trial code
- NCT07384897
- Record updated
- 3 February 2026
- Original description
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).Read full original descriptionShow less
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).
The investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.
Although recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.
The knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.
Inclusion: Diagnosis of lung cancer; Presence of precancerous lung lesions; Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease [COPD]) prior to any treatment; Control group: individuals without known lung disease; Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD); Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected.
Exclusion: Systemic corticosteroid therapy > 10 mg/day prednisone (or equivalent); Chronic inflammatory lung disease currently treated with immunosuppressive therapy; Acute infection at the time of inclusion; Refusal or inability to provide informed consent (or assent, when applicable).